LIMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liminatus Pharma Inc (LIMN) is not a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. The stock is under clear listing pressure, the trend is bearish, and there is no strong proprietary buy signal. For an impatient investor who does not want to wait for a better entry, this is a sell/avoid situation rather than a buy.
Pre-market price is 0.179, down 0.56%, which shows weak immediate momentum. MACD is below zero and still negatively contracting, confirming bearish momentum is not improving. RSI_6 at 45.748 is neutral, so there is no oversold rebound signal to support a buy. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which is a negative trend structure. Price is below the pivot at 0.226 and closer to support at 0.139 than resistance, but the broader setup remains weak despite the short-term candlestick model suggesting possible modest upside. Overall, the technical picture is bearish.
The only near-term positive item is the company’s stated plan to appeal the Nasdaq delisting notice, which could create a temporary speculative bounce if sentiment improves. The stock trend model also suggests a 70% probability of a small upside move over the next day, week, and month.
Liminatus Pharma received a Nasdaq delisting notice for failing to comply with continued listing rules, and it was previously notified about market value non-compliance. This is the dominant catalyst and signals serious listing and business-risk pressure. Hedge funds are neutral, insiders are neutral, and there is no strong institutional buying trend. No congress trading data is available. The lack of valuation data and financial snapshot also adds uncertainty.
Latest quarter financials are not available due to a data error, so growth trends cannot be confirmed. Because the most recent quarterly figures are missing, there is no evidence here of improving revenue, profitability, or balance sheet strength. For a long-term investor, the absence of usable financial momentum data is a major drawback.
No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support the stock. Based on the available information, the Wall Street pros side would likely be cautious to negative because of the Nasdaq delisting notice and weak technical structure, while the cons side is clearly stronger due to listing risk, neutral insider/hedge fund activity, and lack of fundamental support.
